Impact of pharmacist led interventions for drug related problems among chronic kidney disease patients: A randomized control trial

INTERVENTION: In the randomized control trial, patients meeting the inclusion criteria will be randomly assigned to control group and intervention group after taking consent for participation in the study. Data collection form will be designed and developed in order to record patient demographics, medications history, prescribed drugs and laboratory parameters, stages of chronic kidney disease based on Cockgraft Gault Equation. Patient quality of life will be assessed by using a Functional Assessment of Non‐Life Threatening Conditions [FANLTC] (Version 4) questionnaire at baseline and also at end of study (12 week). The patients in control group will be having usual medication and usual care as per their routine without any involvement of pharmacist or counseling. The patients in the intervention group will be given a counseling session by the pharmacist regarding disease knowledge, medication reconciliation, need of dose adjustment and drug‐interactions in CKD patients, and its impact on disease progression and quality of life (QOL), where needed either during hospital stay or at the time of discharge, anticipated to take up to 15 to 20 minutes . Drug related problems and levels of Pharmacy Intervention will be classified, based on the Pharmaceutical Care Network Europe [PCNE] Scale version 9.1, British National Formulary [BNF] will be used to identify drugs requiring special renal dose adjustments while drug interactions will be assessed by using Lexicomp Up to date Software. At end point (12 weeks) the patient quality of life will be assessed by using Functional Assessment of Non‐Life Threatening Condition [FANLTC] questionnaire. CONDITION: chronic kidney disease;Other renal associated disorders;Other cardiovascular diseases;Diabetes;renal and urogenital disorders; ; chronic kidney disease ; Other renal associated disorders ; Other cardiovascular diseases ; Diabetes ; renal and urogenital disorders Renal and Urogenital ‐ Other renal and urogenital disorders PRIMARY OUTCOME: Impact of pharmacist led interventions for drug related problems (including dose related, drug interactions, side effect or if any) in chronic kidney disease patients will be classified based on the Pharmaceutical care network Europe association PCNE scale version 9.1[At baseline (0 week) and endpoint (12 week) post randomization] SECONDARY OUTCOME: Assessment for Quality of Life of chronic kidney disease patients will be conducted using the Functional Assessment of Non‐Life Threatening Conditions [FANLTC] (version 4) questionnaire to compare the impact of pharmacist counseling and adjustment of drug related problems.[At baseline (0 week) and end point (12 week) post randomization] INCLUSION CRITERIA: Participants of this RCT must be adult patients of 18 years and above, both genders who currently had or previously diagnosed with all stages of renal disease.